ДЕПО-ФОРМА ЛЕЙПРОРЕЛИНА АЦЕТАТА (ЭЛИГАРД) В ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ: ЧТО ВЫИГРЫВАЮТ ПАЦИЕНТЫ?
https://doi.org/10.17650/1726-9776-2010-6-4-71-77
Аннотация
Об авторах
В. Б. МатвеевРоссия
М. И. Волкова
Россия
Д. З. Купчан
Россия
Я. В. Гриднева
Россия
Список литературы
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 году. М., 2009.
2. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
3. Chrisp P., Sorkin E.M. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991;1:487–509.
4. Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–57.
5. Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533–6.
6. Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007;100(Suppl. 1):6–11.
7. Painter M.R. Reimbursement issues with hormonal therapies for prostate cancer. Rev Urol 2005;7:44–7.
8. Berges R. Eligard: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl 2005;4:20–5.
9. Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021–4.
10. Lin B.J., Chen K.K., Chen M.T., Chang L.S. The time for serum testosterone to reach castrate level after bilateral orchidectomy or oral estrogen in the management ofmetastatic prostatic cancer. Urology 1994;43:834–7.
11. Oefelein M.G., Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164:726–9.
12. McLeod D., Zinner N., Tomera K. et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756–61.
13. Esquena S., Abascal J.M., Trilla E., Morote J. Failure of luteinising hormonal releasing hormonal agonist therapy to achieve castration. Does it exist? Eur Urol Suppl 2004;3:57;
14. Wechsel H.W., Zerbib M., Pagano F., Coptcoat M.J. Randomized open labeled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 1996;30(suppl 1):7–14.
15. Kawakami J., Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 2002;167(suppl 4):288.
16. Zinner N.R., Bidair M., Centeno A., Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004;64:1177–81.
17. Sharifi R., Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002;168:1001–4.
18. Perez-Marreno R., Chu F.M., Gleason D. et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902–14.
19. Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199–203.
20. Kienle E., Lubben G. Efficacy and safety of leuprorein depot for prostate cancer. Urol Int 1996;56 (Suppl 1):23–30.
21. Bischoff W., German Leuprorelin Study Group. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostate cancer: preliminary report. J Int Med Res 1990;18(Suppl 1):103–13.
22. Crawford E.D., Blumenstein B.A., Goodman P.J. et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990;66(5 Suppl):1039–44.
23. Sharifi R., Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 1990;143(1): 68–71.
24. Sato K., Akakura S., Isaka H. et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study. Urology 2004;64(2):341–5.
25. Heyns C.F., Simonin M.P., Grosgurin P. et al. For the South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92(3):226–31.
26. McLeod D., Zinner N., Tomera K. et al. Aberalix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756–61.
27. Trachtenberg J., Gittleman M., Steidle C. et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167(4):1670–4.
28. Parmar H., Lightman S.L., Allen L. et al. Randomised controlled study of orchidectomy vs. long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 1985;2:1201–5.
29. Jerome S., David J. Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566–77.
30. Аbbou C.C., Lucas C., Leblanc V. Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer. Prog Urol 1997;7(6):984–95.
Рецензия
Для цитирования:
Матвеев В.Б., Волкова М.И., Купчан Д.З., Гриднева Я.В. ДЕПО-ФОРМА ЛЕЙПРОРЕЛИНА АЦЕТАТА (ЭЛИГАРД) В ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ: ЧТО ВЫИГРЫВАЮТ ПАЦИЕНТЫ? Онкоурология. 2010;6(4):71-77. https://doi.org/10.17650/1726-9776-2010-6-4-71-77
For citation:
Matveev V.B., Volkova M.I., Kupchan D.Z., Gridneva Ya.V. LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN? Cancer Urology. 2010;6(4):71-77. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-4-71-77